Brain cancer vaccine shows promise in early trial
NCT ID NCT04801147
First seen Mar 31, 2026 · Last updated May 15, 2026 · Updated 7 times
Summary
This study tested a personalized vaccine made from a patient's own tumor cells and immune cells (dendritic cells) for people with newly diagnosed glioblastoma, an aggressive brain cancer. The goal was to see if the treatment is safe and can help delay tumor growth. 76 participants received the vaccine after standard surgery and chemo-radiation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UOC Neuro-oncologia Molecolare
Milan, Milano, 20133, Italy
Conditions
Explore the condition pages connected to this study.